Glaser N S, Styne D M
Department of Pediatrics, University of California, Davis School of Medicine, Sacramento 95817, USA.
J Clin Endocrinol Metab. 1997 Jun;82(6):1719-26. doi: 10.1210/jcem.82.6.3986.
Children with hyperthyroidism often require prolonged courses of antithyroid medication to achieve remission, and long-term compliance is problematic. To determine which clinical and laboratory features predict early remission, we reviewed the records of 191 patients less than 19 yr old with Graves' disease. We compared patients achieving remission within 2 yr (group 1, n = 27) with those who completed more than 2 yr of medical therapy but did not achieve a remission (group 2, n = 79). Patients who were in neither of the above categories (n = 85) were excluded from the statistical analysis. Variables that were measurable at the time of diagnosis, recorded in more than 50% of the study population and associated with early remission in the univariate analysis (P < or = 0.05), were entered into a stepwise multiple logistic regression analysis. Variables retaining a significant association with early remission (P < 0.05) were considered independent predictors of early remission. Patients achieving early remission were older (mean, 12.5 vs. 10.9 yr, P = 0.039) and had higher body mass indexes (BMI, 19.0 vs. 16.6, P = 0.002), higher BMI SD scores (-0.03 vs. -0.60, P = 0.004), lower heart rates (110 vs. 121, P = 0.023), smaller goiters (group 1: 60% with moderate/large goiter; group 2: 83%, P = 0.050), lower platelet counts (272 vs. 339 K/microL, P = 0.006), lower serum T4 and T3 concentrations at presentation (T4: 18.3 vs. 22.5 microg/dL, P = 0.015; T3: 439 vs. 613 ng/dL, P = 0.008), and were less likely to have a positive test for thyroid stimulating Igs (group 1: 50% vs. group 2: 93%, P = 0.008). Regression analysis identified BMI SD score and goiter size as independent predictors of early remission (P < 0.05). Eighty-six percent of patients with BMI SD score above -0.5 SD and minimal/small goiters achieved early remission, compared with 13% of those with BMI SD score below -0.5 SD and moderate/large goiters. We conclude that, of multiple clinical and laboratory variables associated with early remission, BMI SD score and goiter size are independent predictors. Algorithms employing these two variables can be used to facilitate counseling of patients and expedite therapeutic decisions.
患有甲状腺功能亢进症的儿童通常需要长期服用抗甲状腺药物以实现病情缓解,而长期的依从性存在问题。为了确定哪些临床和实验室特征可预测早期缓解,我们回顾了191例年龄小于19岁的格雷夫斯病患者的记录。我们将在2年内实现缓解的患者(第1组,n = 27)与完成超过2年药物治疗但未实现缓解的患者(第2组,n = 79)进行了比较。不属于上述任何一类的患者(n = 85)被排除在统计分析之外。在诊断时可测量、在超过50%的研究人群中记录且在单因素分析中与早期缓解相关(P≤0.05)的变量,被纳入逐步多元逻辑回归分析。与早期缓解保持显著关联(P < 0.05)的变量被视为早期缓解的独立预测因素。实现早期缓解的患者年龄较大(平均12.5岁对10.9岁,P = 0.039),体重指数(BMI)较高(19.0对16.6,P = 0.002),BMI标准差分数较高(-0.03对-0.60,P = 0.004),心率较低(110对121,P = 0.023),甲状腺肿较小(第1组:60%有中度/大甲状腺肿;第2组:83%,P = 0.050),血小板计数较低(272对339 K/微升,P = 0.006),就诊时血清T4和T3浓度较低(T4:18.3对22.5微克/分升,P = 0.015;T3:439对613纳克/分升,P = 0.008),且甲状腺刺激免疫球蛋白检测呈阳性的可能性较小(第1组:50%对第2组:93%,P = 0.008)。回归分析确定BMI标准差分数和甲状腺肿大小为早期缓解的独立预测因素(P < 0.05)。BMI标准差分数高于-0.5标准差且甲状腺肿最小/小的患者中,86%实现了早期缓解,而BMI标准差分数低于-0.5标准差且甲状腺肿中度/大的患者中这一比例为13%。我们得出结论,在与早期缓解相关的多个临床和实验室变量中,BMI标准差分数和甲状腺肿大小是独立预测因素。采用这两个变量的算法可用于方便对患者进行咨询并加快治疗决策。